Drugs / soluble β-1,3/1,6-glucan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00288392 | Jun 2005 → Sep 2006 | ulcer of lower limbs | Biotec Pharmacon ASA | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | soluble β-1,3/1,6-glucan | “AIMS/INTRODUCTION: Dysregulated inflammatory response is believed to be an important factor in the pathogenesis of several late complications of diabetes mellitus. β-Glucans...” PMID 25411598 ↗ Dec 2013 |
| Known as | SBG | “AIMS/INTRODUCTION: Dysregulated inflammatory response is believed to be an important factor in the pathogenesis of several late complications of diabetes mellitus. β-Glucans...” PMID 25411598 ↗ Dec 2013 |
| Route | Topical | “Macrophage stimulating agent soluble yeast β-1,3/1,6-glucan as a topical treatment of diabetic foot and leg ulcers” PMID 25411598 ↗ Dec 2013 |